These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 5112463)
21. Long-term treatment of Parkinsonism with L-dopa. Presthus J; Holmsen R Acta Neurol Scand Suppl; 1972; 51():131-2. PubMed ID: 4514340 [No Abstract] [Full Text] [Related]
22. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University). Gutmann L; Martin JD; Gutrecht JA W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660 [No Abstract] [Full Text] [Related]
23. The clinical use of levodopa in the treatment of Parkinson's disease. McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056 [No Abstract] [Full Text] [Related]
24. [Results of treatment of Parkinsonism with L-dopa]. De Divitiis E; D'Andrea F; Signorelli CD Sist Nerv; 1970; 22(2):99-108. PubMed ID: 5504563 [No Abstract] [Full Text] [Related]
25. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine]. Sigwald J; Raymondeaud C; Piot C Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718 [No Abstract] [Full Text] [Related]
26. Therapeutic uses and side effects of L-dopa. Boshes B Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081 [No Abstract] [Full Text] [Related]
27. [L-dopa treatment of persons with parkinsonism in a hospital for geriatric rehabilitation]. Antonini F; Baroni A; Roveyaz L Sist Nerv; 1970; 22(2):74-81. PubMed ID: 5504560 [No Abstract] [Full Text] [Related]
28. Parkinson's disease treated with L-dopa. Three-year follow-up report. Mones RJ N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706 [No Abstract] [Full Text] [Related]
29. [Treatment with L-dopa in Parkinsonian syndromes]. De Renzi E; Pieczuro A Sist Nerv; 1970; 22(1):1-11. PubMed ID: 5502951 [No Abstract] [Full Text] [Related]
30. L-Dopa in the treatment of Parkinson's disease. Landy PJ Med J Aust; 1970 Oct; 2(14):632-4. PubMed ID: 5477807 [No Abstract] [Full Text] [Related]
31. L-dopa for postencephalitic Parkinsonism. Krasner N; Cornelius JM Br Med J; 1970 Nov; 4(5733):496. PubMed ID: 5481239 [No Abstract] [Full Text] [Related]
32. Response of patients with postencephalitic Parkinsonism to levodopa. Duvoisin RC; Lobo-Antunes J; Yahr MD J Neurol Neurosurg Psychiatry; 1972 Aug; 35(4):487-95. PubMed ID: 5049808 [TBL] [Abstract][Full Text] [Related]
33. Failures of L-dopa. Paulson GW Ohio State Med J; 1973 Dec; 69(12):896-8. PubMed ID: 4769406 [No Abstract] [Full Text] [Related]
34. Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance. Völler GW; Muschard F Acta Neurol Scand; 1974; 50(3):391-3. PubMed ID: 4525037 [No Abstract] [Full Text] [Related]
35. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081 [No Abstract] [Full Text] [Related]
36. A quantitative evaluation of the effects of L-dopa on Parkinson's disease. Velasco F; Velasco M Neuropharmacology; 1973 Feb; 12(2):89-99. PubMed ID: 4595553 [No Abstract] [Full Text] [Related]
37. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy. Lipman IJ; Papadopoulos NM Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194 [No Abstract] [Full Text] [Related]